Brian Zambrowicz

Executive Vice President, VelociGene and Drug Safety and Pharmacometrics · Regeneron Pharmaceuticals

Biopharmaceuticals

Brian Zambrowicz is executive vice president of VelociGene and drug safety and pharmacometrics at Regeneron Pharmaceuticals. He joined in 2015 after nearly two decades at Lexicon Pharmaceuticals, where he became executive vice president and chief scientific officer.

Last reviewed: Oct 21, 2026

Brian Zambrowicz

Executive Vice President, VelociGene and Drug Safety and Pharmacometrics Regeneron Pharmaceuticals

Last Reviewed: October 21, 2026

Executive Summary

Brian Zambrowicz is executive vice president of VelociGene and drug safety and pharmacometrics at Regeneron Pharmaceuticals. He joined in 2015 after nearly two decades at Lexicon Pharmaceuticals, where he became executive vice president and chief scientific officer.

Career Highlights

  • Joined Regeneron in 2015.
  • Leads functional genomics, VelociGene operations, drug safety and pharmacometrics.
  • Previously served as executive vice president and chief scientific officer at Lexicon Pharmaceuticals.

Professional Journey

Zambrowicz worked at Lexicon Pharmaceuticals from 1996 to 2015. He held positions of increasing responsibility and ultimately served as executive vice president and chief scientific officer.

He joined Regeneron in 2015. His current responsibilities cover functional genomics and VelociGene operations, together with drug safety and pharmacometrics. The portfolio combines research technologies with the scientific evaluation of drug safety and drug effects.

His career brings doctoral scientific training and prior chief scientific officer experience into executive leadership of these functions at Regeneron. The current visible company title includes drug safety and pharmacometrics, extending beyond older descriptions focused on functional genomics.

Education

Zambrowicz earned a BS from the University of Wisconsin–Madison and a PhD from the University of Washington.